Literature DB >> 12813612

Application of the 1998 Canadian cholesterol guidelines to a military population: health benefits and cost effectiveness of improved cholesterol management.

Johanna N Spaans1, Douglas Coyle, George Fodor, Rama Nair, Régis Vaillancourt, Steven A Grover, Louis Coupal.   

Abstract

OBJECTIVE: To determine whether statins are underprescribed in the Canadian military. The cost effectiveness of statin therapy in patients identified by the 1998 Canadian cholesterol interim guidelines was also explored.
METHODS: Charts of 1424 Canadian military personnel (age 45 or older) were reviewed at 11 Canadian bases. Risk factors and cholesterol values were used to identify drug therapy candidates. Cost effectiveness ratios and health benefits in terms of years of life saved for statin therapy were estimated for the candidates using a validated cardiovascular disease life expectancy model.
RESULTS: Of the 1313 personnel not on lipid lowering medication, 172 were identified as drug therapy candidates. An average of 2.89 years of life saved was forecast for the identified personnel, at an average cost of less than 10,000 dollars per year of life saved.
CONCLUSIONS: The health benefits of statin therapy in this population are substantial and the cost effectiveness is acceptable. Statin therapy warrants greater attention as a preventive strategy for coronary artery disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12813612

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  2 in total

Review 1.  Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.

Authors:  Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf H Klungel
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.

Authors:  Paul Kolm; Yong Yuan; Emir Veledar; Shamir R Mehta; Judith A O'Brien; William S Weintraub
Journal:  Can J Cardiol       Date:  2007-11       Impact factor: 5.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.